Terbutaline 1-sulfate | 1273567-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: Terbutaline 1-sulfate
• 英文别名: [2-(tert-butylamino)-1-(3,5-dihydroxyphenyl)ethyl] hydrogen sulfate
• CAS: 1273567-75-1
• 化学式: C₁₂H₁₉NO₆S
• 分子量: 305.35
• InChiKey: CFUSMTBQBWPGOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Therapeutic applications of beta-adrenergic agonists
  申请人：The Rowett Research Institute

  公开号：EP0308157A2

  公开（公告）日：1989-03-22

  This invention relates to novel therapeutic uses of beta-­adrenergic agonists in humans and animals. The uses include increasing muscle growth and reducing fat uptake from dietary input, retarding or reversing atrophy of denervated muscle, alleviating or reversing the effects of various diseases (including cancer), modification of foetal and neonatal growth, and possible genetic modifications of the developing foetus. The preferred beta-adrenergic agonist is clenbuterol. Surprisingly, the beta-adrenergic agonist can be mixed with a beta-adrenergic antagonist to obviate or mitigate unwanted side-effects without excessively inhibiting the wanted novel effects.

  本发明涉及β-肾上腺素能激动剂在人类和动物中的新型治疗用途。 这些用途包括增加肌肉生长和减少从饮食中摄取脂肪，延缓或逆转肌肉萎缩，减轻或逆转各种疾病（包括癌症）的影响，改变胎儿和新生儿的生长，以及对发育中的胎儿进行可能的基因改造。 令人惊奇的是，β-肾上腺素能激动剂可与β-肾上腺素能拮抗剂混合使用，以避免或减轻不希望出现的副作用，同时又不会过度抑制想要达到的新效果。
• Use of beta-adrenergic agonists for treating loss of function of striated muscles
  申请人：The Rowett Research Institute

  公开号：EP0662324A1

  公开（公告）日：1995-07-12

  This invention relates to novel therapeutic uses of beta-adrenergic agonists in humans and animals. The uses include increasing muscle growth and reducing fat uptake from dietary input, retarding or reversing atrophy of denervated muscle, alleviating or reversing the effects of various diseases (including cancer), modification of foetal and neonatal growth, and possible genetic modifications of the developing foetus. The preferred beta-adrenergic agonist is clenbuterol. Surprisingly, the beta-adrenergic agonist can be mixed with a beta-adrenergic antagonist to obviate or mitigate unwanted side-effects without excessively inhibiting the wanted novel effects.

  本发明涉及β-肾上腺素能激动剂在人类和动物中的新型治疗用途。这些用途包括增加肌肉生长和减少从饮食中摄取脂肪，延缓或逆转肌肉萎缩，减轻或逆转各种疾病（包括癌症）的影响，改变胎儿和新生儿的生长，以及对发育中的胎儿进行可能的基因改造。 首选的β-肾上腺素能激动剂是克伦特罗。 令人惊奇的是，β-肾上腺素能激动剂可与β-肾上腺素能拮抗剂混合使用，以避免或减轻不希望出现的副作用，同时又不会过度抑制想要达到的新效果。
• Methods of treating pain and compositions for use therefor
  申请人：TheraQuest Biosciences, LLC

  公开号：US20040209850A1

  公开（公告）日：2004-10-21

  The present invention relates to a method of treating or preventing pain and to pharmaceutical compositions useful for carrying out said methods. The present invention is directed to a method of treating or preventing pain comprising administering a selected analgesic and a beta adrenergic agonist to a subject in need of such treatment, wherein said beta adrenergic agonist produces an enhanced effect of said analgesic. The present invention is also directed to pharmaceutical compositions comprising an analgesic and a beta adrenergic agonist useful for carrying out the method of the present invention.
• US5541188A
  申请人：——

  公开号：US5541188A

  公开（公告）日：1996-07-30
• US5530029A
  申请人：——

  公开号：US5530029A

  公开（公告）日：1996-06-25